Overexpression of the secretory small GTPase Rab27B in human breast cancer correlates closely with lymph node metastasis and predicts poor prognosis

Journal of Translational Medicine

Shi-Juan Mai⁴  Dan Xie³  Yi-Xin Zeng⁴  Ma-Yan Huang³  Ding-Zhun Liao³  Hai-Xia Deng⁴  Yi-Ji Liao⁴  Dong Qian⁴  Jie-Wei Chen³  Zhu-Ting Tong¹  Man-Bo Cai²  Xiao-Xia Huang³  Jia-Xing Zhang⁴ 

[1]Department of Radiotherapy, The First Affiliated Hospital, Anhui Medical University, Hefei, China

[2]Cancer Center, The First Affiliated Hospital, University of South China, Hengyang, China

[3]Department of Pathology, Cancer Center, Sun Yat-Sen University, 651# Dongfeng Road East, Guangzhou, 510060, China

[4]State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University, 651# Dongfeng Road East, Guangzhou, 510060, China

关键词: Metastasis;    EMT;    Prognosis;    Breast cancer;    Rab27B;   

Others  :  1205889
DOI  :  10.1186/1479-5876-10-242

 received in 2012-08-24, accepted in 2012-11-28,  发布年份 2012

【 摘 要 】

Background

The secretory small GTPase Rab27b was recently identified as an oncogene in breast cancer (BC) in vivo and in vitro studies. This research was designed to further explore the clinical and prognostic significance of Rab27B in BC patients.

Methods

The mRNA/protein expression level of Rab27B was examined by performing Real-time PCR, western blot, and immunohistochemistry (IHC) assays in 12 paired BC tissues and matched adjacent noncancerous tissues (NAT). Then we carried out IHC assay in a large cohort of 221 invasive BC tissues, 22 normal breast tissues, 40 fibroadenoma (FA), 30 ductual carcinoma in situ (DCIS) and 40 metastatic lymph nodes (LNs). The receiver operating characteristic curve method was applied to obtain the optimal cutoff value for high Rab27B expression. Epithelial-mesenchymal transition (EMT) marker expression levels were detected in relation to Rab27B expression.

Results

We observed that the increased expression of Rab27B was dependent upon the magnitude of cancer progression (P < 0.001). The elevated expression of Rab27B was closely correlated with lymph node metastasis, advanced clinical stage, ascending pathology classification, and positive ER status. Furthermore, patients with high expression of Rab27B had inferior survival outcomes. Multivariate Cox regression analysis proved that Rab27B was a significantly independent risk factor for patients’ survival (P < 0.001). Furthermore, a significant positive relationship was observed between Rab27B expression and elevated mesenchymal EMT markers.

Conclusion

Our findings suggest that overexpression of Rab27B in BC coincides with lymph node metastasis and acquisition of a poor prognostic phenotype.

【 授权许可】

   
2012 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Yang L, Li LD, Chen YD, Parkin DM: Time trends, estimates and projects for breast cancer incidence and mortality in China. Zhonghua Zhong Liu Za Zhi 2006, 28:438-440.
• [2]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
• [3]Bombonati A, Sgroi DC: The molecular pathology of breast cancer progression. J Pathol 2011, 223:307-317.
• [4]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
• [5]Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC: American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
• [6]Fukuda M: Regulation of secretory vesicle traffic by Rab small GTPases. Cell Mol Life Sci 2008, 65:2801-2813.
• [7]Pereira-Leal JB, Seabra MC: Evolution of the Rab family of small GTP-binding proteins. J Mol Biol 2001, 313:889-901.
• [8]Zerial M, McBride H: Rab proteins as membrane organizers. Nat Rev Mol Cell Biol 2001, 2:107-117.
• [9]Pfeffer SR: Structural clues to Rab GTPase functional diversity. J Biol Chem 2005, 280:15485-15488.
• [10]Stenmark H: Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 2009, 10:513-525.
• [11]Chen D, Guo J, Miki T, Tachibana M, Gahl WA: Molecular cloning and characterization of rab27a and rab27b, novel human rab proteins shared by melanocytes and platelets. Biochem Mol Med 1997, 60:27-37.
• [12]Westbroek W, Lambert J, De Schepper S, Kleta R, Van Den Bossche K, Seabra MC, Huizing M, Mommaas M, Naeyaert JM: Rab27b is up-regulated in human Griscelli syndrome type II melanocytes and linked to the actin cytoskeleton via exon F-Myosin Va transcripts. Pigment Cell Res 2004, 17:498-505.
• [13]Jordens I, Westbroek W, Marsman M, Rocha N, Mommaas M, Huizing M, Lambert J, Naeyaert JM, Neefjes J: Rab7 and Rab27a control two motor protein activities involved in melanosomal transport. Pigment Cell Res 2006, 19:412-423.
• [14]Westbroek W, Tuchman M, Tinloy B, De Wever O, Vilboux T, Hertz JM, Hasle H, Heilmann C, Helip-Wooley A, Kleta R, Gahl WA: A novel missense mutation (G43S) in the switch I region of Rab27A causing griscelli syndrome. Mol Genet Metab 2008, 94:248-254.
• [15]Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB: The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004, 10:1251-1256.
• [16]Kanda I, Nishimura N, Nakatsuji H, Yamamura R, Nakanishi H, Sasaki T: Involvement of Rab13 and JRAB/MICAL-L2 in epithelial cell scattering. Oncogene 2008, 27:1687-1695.
• [17]Liu YJ, Wang Q, Li W, Huang XH, Zhen MC, Huang SH, Chen LZ, Xue L, Zhang HW: Rab23 is a potential biological target for treating hepatocellular carcinoma. World J Gastroenterol 2007, 13:1010-1017.
• [18]Hou Q, Wu YH, Grabsch H, Zhu Y, Leong SH, Ganesan K, Cross D, Tan LK, Tao J, Gopalakrishnan V, Tang BL, Kon OL, Tan P: Integrative genomics identifies RAB23 as an invasion mediator gene in diffuse-type gastric cancer. Cancer Res 2008, 68:4623-4630.
• [19]Fukui K, Tamura S, Wada A, Kamada Y, Igura T, Kiso S, Hayashi N: Expression of Rab5a in hepatocellular carcinoma: possible involvement in epidermal growth factor signaling. Hepatol Res 2007, 37:957-965.
• [20]Bravo-Cordero JJ, Marrero-Diaz R, Megias D, Genis L, Garcia-Grande A, Garcia MA, Arroyo AG, Montoya MC: MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway. EMBO J 2007, 26:1499-1510.
• [21]Wang JS, Wang FB, Zhang QG, Shen ZZ, Shao ZM: Enhanced expression of Rab27A gene by breast cancer cells promoting invasiveness and the metastasis potential by secretion of insulin-like growth factor-II. Mol Cancer Res 2008, 6:372-382.
• [22]Chia WJ, Tang BL: Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta 2009, 1795:110-116.
• [23]Hendrix A, Maynard D, Pauwels P, Breams G, Denys H, Van den Broecke R, Lambert J, Van Belle S, Cocquyt V, Gespach C, Brache M, Seabra MC, Gahl WA, De Wever O, Westbroek W: Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst 2010, 102:866-880.
• [24]Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin North Am 2003, 83:803-819.
• [25]Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, Fu J, Zeng MS, Yun JP, Wu QL, Zeng YX, Shao JY: Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res 2011, 13:R2. BioMed Central Full Text
• [26]Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, Huang WL, Zeng YX, Shao JY: miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 2011, 71:3552-3562.
• [27]Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360.
• [28]Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A: Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007, 60:1112-1116.
• [29]Dong WW, Mou Q, Chen J, Cui JT, Li WM, Xiao WH: Differential expression of Rab27A/B correlates with clinical outcome in hepatocellular carcinoma. World J Gastroenterol 2012, 18:1806-1813.
• [30]Mignot G, Chalmin F, Ladoire S, Rebe C, Ghiringhelli F: Tumor exosome-mediated MDSC activation. Am J Pathol 2011, 178:1403-1404. author reply 1404–1405
• [31]Ochieng J, Pratap S, Khatua AK, Sakwe AM: Anchorage-independent growth of breast carcinoma cells is mediated by serum exosomes. Exp Cell Res 2009, 315:1875-1888.
• [32]Hegmans JP, Bard MP, Hemmes A, Luider TM, Kleijmeer MJ, Prins JB, Zitvogel L, Burgers SA, Hoogsteden HC, Lambrecht BN: Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol 2004, 164:1807-1815.
• [33]Cho JA, Park H, Lim EH, Lee KW: Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int J Oncol 2012, 40:130-138.
• [34]Arias AM: Epithelial mesenchymal interactions in cancer and development. Cell 2001, 105:425-431.
• [35]Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.